GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » GF Score

ECOR (electroCore) GF Score : 76/100 (As of Mar. 24, 2025)


View and export this data going back to 2018. Start your Free Trial

What is electroCore GF Score?

electroCore has the GF Score of 76, which implies that the company is Likely to have average performance.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 3/10
3. Growth Rank : 10/10
4. GF Value Rank : 9/10
5. Momentum Rank : 3/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes electroCore is Likely to have average performance.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of electroCore's GF Score

For the Medical Devices subindustry, electroCore's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


electroCore's GF Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, electroCore's GF Score distribution charts can be found below:

* The bar in red indicates where electroCore's GF Score falls into.



electroCore  (NAS:ECOR) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


electroCore GF Score Related Terms

Thank you for viewing the detailed overview of electroCore's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


electroCore Business Description

Traded in Other Exchanges
N/A
Address
200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Executives
Daniel S Goldberger director, officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Thomas J. Errico director, 10 percent owner 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 97920
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Joseph P Errico director, 10 percent owner, officer: See Remarks 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Trevor J Moody director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Julie Ann Goldstein director 205 FORGE WAY, ROCKAWAY NJ 07866
Patricia Wilber director 205 FORGE WAY, SUITE 205, ROCKAWAY NJ 07866
Brian M Posner officer: Chief Financial Officer 1590 REED ROAD, PENNINGTON NJ 08534
Tullis James L L director 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
F Peter Cuneo director 10 EAST 40TH ST, NEW YORK NY 10016
Stephen Ondra director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Nicholas Colucci director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Michael G Atieh director MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033